BRIEF-Celgene's experimental cancer drug meets main goal of a late-stage study

Oct 2 (Reuters) - Celgene Corp :

* Abraxane meets primary endpoint of progression-free survival in phase III

chemotherapy-naïve metastatic melanoma study

* The safety profile of abraxane observed in the ca033 study is consistent with

other abraxane pivotal clinical trials

((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))

((For more news, please click here ))